F S&P 500
5,294.00 -30.75 (-0.58%) F Dow Jones
38,715.00 -229.00 (-0.59%) F Nasdaq
18,820.50 -120.00 (-0.63%) E-mini Russell 2000 Index Futur
2,053.30 -19.90 (-0.96%) Petróleo
80.40 +0.57 (+0.71%) Oro
2,342.10 -14.40 (-0.61%)
ABVC BioPharma, Inc. (ABVC)
Fuera de horario:
ABVC BioPharma, Inc.
44370 Old Warm Springs Boulevard
Fremont, CA 94538
United States
(510)-668-0881
https://www.abvcpharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 16
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Eugene Jiang | Chairman & Chief Business Officer | 200k | N/D | 1986 |
| Dr. Uttam Yashwant Patil Ph.D. | Chief Executive Officer | N/D | N/D | 1986 |
| Mr. Leeds Chow | CFO & Principal Accounting Officer | 180k | N/D | 1989 |
| Dr. Tsung-Shann Jiang EMBA, Ph.D. | Chief Scientific Officer, Chief Strategy Officer & Director | 200k | N/D | 1954 |
Descripción
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
Gestión corporativa
La calificación ISS Governance QuickScore de ABVC BioPharma, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
